Xanthohumol microbiome and signature in adults with Crohn’s disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial

Peer Review reports

Original Submission
14 May 2022	Submitted	Original manuscript
9 Jun 2022	Reviewed	Reviewer Report - Kirsty Loudon
15 Jun 2022	Author responded	Author comments - Blake Langley
Resubmission - Version 2
15 Jun 2022	Submitted	Manuscript version 2
Publishing
21 Sep 2022	Editorially accepted
22 Oct 2022	Article published	10.1186/s13063-022-06782-z

Back to article page